{"classes":[{"categories":[{"measurements":[{"comment":"not enough events to allow for calculation","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"82.7"},{"comment":"not enough events to allow for calculation","groupId":"OG001","lowerLimit":"91.00","upperLimit":"NA","value":"NA"},{"comment":"not enough events to allow for calculation","groupId":"OG002","lowerLimit":"58.6","upperLimit":"NA","value":"NA"},{"comment":"not enough events to allow for calculation","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"not enough events to allow for calculation","groupId":"OG004","lowerLimit":"79.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"OS was defined as the time between start of treatment and the death/censored date. Participants who died (regardless of the cause of death) were considered to have an event. Participants who were alive at the end of the study, and participants who were lost to follow-up, were censored at the last date when subjects were known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Sotatercept 0.1 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to either the 0.1 mg/kg arm or the 0.3 mg/kg arm. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 0.5 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG000","title":"Sotatercept 0.1 mg/kg"},{"description":"Sotatercept 0.3 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to either the 0.1 mg/kg arm or the 0.3 mg/kg arm. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 0.5 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG001","title":"Sotatercept 0.3 mg/kg"},{"description":"Sotatercept 0.5 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/6 subjects in Cycle 1 in the 0.5 mg/kg treatment group, the 1.0 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG002","title":"Sotatercept 0.5 mg/kg"},{"description":"Sotatercept 1.0 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/6 subjects in Cycle 1 in the 1.0 mg/kg treatment group, the 2.0 mg/kg treatment group began inclusion in the randomization scheme. Following evaluation of all treatment group data by the Steering Committee, enrollment continued only in the 1.0 mg/kg arm because the arm had the greatest frequency of erythroid hematological improvement (HI-E).","id":"OG003","title":"Sotatercept 1.0 mg/kg"},{"description":"Sotatercept 2.0 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. The 2.0 mg/kg sotatercept dose was reduced to 1.5 mg/kg for ongoing and newly enrolled participants by protocol amendment.","id":"OG004","title":"Sotatercept 2.0 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population","reportingStatus":"POSTED","timeFrame":"Day 1 to 257.3 weeks","title":"Kaplan-Meier Estimates for Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"weeks"}